Marshall Wace, LLP Rockwell Medical, Inc. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.23 - $1.86 $95,039 - $143,718	-77,268 Reduced 44.13%	97,828 $162,000
Q4 2023 Feb 14, 2024	SELL	$1.58 - $2.44 $105,551 - $163,004	-66,805 Reduced 27.62%	175,096 $330,000
Q3 2023 Nov 14, 2023	BUY	$1.83 - $6.19 $413,203 - $1.4 Million	225,794 Added 1401.84%	241,901 $503,000
Q2 2023 Aug 14, 2023	BUY	$1.8 - $5.46 $28,992 - $87,944	16,107 New	16,107 $87,000

6.28M

11K

32.1K

Ticker RMTI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 10,675,200
Market Cap $39.1M
Description
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iro...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.